PO-0674: Brain relapses in stage III NSCLC after multimodality treatment: prognostic factors from a randomised trial  by Pöttgen, C. et al.
3rd ESTRO Forum 2015                                                                                                                                         S329 
 
derive optimized α and α /β of 0.3Gy-1 and 6Gy, respectively. 
We also found a generalized mean value of a=-1.7 (95% 
confidence interval upper bound=-0.1), which produces the 
best performing gTD predictive metric (Fig.). 
Conclusions: A negative 'a' value suggest that areas of low 
cell survival (high dose) play a driving role in determining 
whether local control is achieved, regardless of dose 
homogeneity. In this first known case of multi-institutional 
investigation of case-specific treatment effects, we 
demonstrated the utility and superior predictive power of 
this novel, biologically-inspired dose-metric. 
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Purpose/Objective: Medically inoperable early stage non-
small cell lung cancer (NSCLC) is frequently treated with 
stereotactic body radiotherapy (SBRT). As this patient 
population is often frail, not only is surgery a potential 
morbid procedure, but obtaining a pathologic diagnosis of 
cancer may be risky as well. It is becoming more common to 
treat patients empirically with growing, positron emission 
tomography (PET) avid lung nodules with SBRT. This study 
looked to compare outcomes between patients with a 
histopathologic diagnosis of cancer compared to patients 
without a diagnosis. 
Materials and Methods: A retrospective review of patients 
enrolled on a prospective IRB-approved registry from 2004 to 
2013 was conducted. Patients with a non-diagnostic biopsy or 
no attempted biopsy were considered to lack a 
histopathologic diagnosis. Patients with synchronous cancers 
or prior invasive malignancy within 2 years of SBRT were 
excluded. Kaplan-Meier curves for local control (LC), 
progression-free survival (PFS), recurrence-free survival 
(RFS), and overall survival (OS) were created by Wilcoxon 
analysis. Patients were evaluated for risk factors predicting 
for LC, PFS, RFS, and OS using Cox regression. 
Results: A total of 427 patients were included in the analysis. 
Median age was 74 years old with a median follow-up of 17 
months (range, 0.2 to 105 months). Of all patients, 332 (78%) 
underwent biopsy confirming diagnosis of malignancy, with 
124 (37%) patients with adenocarcinoma, 98 (30%) patients 
with squamous cell, 98 (30%) patients with NSCLC not 
otherwise specified, and 12 (4%) patients with other 
histologies. Ninety-five patients (22%) were treated 
empirically for suspected lung cancer, of which 92 (97%) were 
staged with PET/CT. Patients treated without a diagnosis 
were more likely to have a prior history of cancer, smaller 
tumors, lower BMI, and a lower PET standardized uptake 
value maximum compared with patients with a diagnosis. 
There was no difference between the groups at baseline with 
regard to age, race, gender, smoking status, Charlson 
comorbidity score, KPS, central location, use of mediastinal 
staging, or use of PET/CT staging. For the entire cohort, 2 
year LC, PFS, RFS and OS was 91%, 47%, 64% and 61%, 
respectively. There was no difference in LC, PFS, RFS, and OS 
between patients with and without biopsy. On multivariate 
analysis, factors predictive for improved OS included KPS ≥70 
{hazard ratio (HR) 0.552 [95% confidence interval (CI), 0.383-
0.796, p=0.005]}, larger CT size of tumor [HR 1.195 (95% CI, 
1.033-1.383), p=0.003] and post-treatment CT scan showing 
partial or complete response [HR 0.399 (95% CI, 0.164-0.968, 
p=0.012)]. 
Conclusions: In carefully selected patients without a biopsy, 
SBRT results in comparable survival and tumor control 
compared with patients treated with a biopsy. 
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Purpose/Objective: To identify prognostic factors for brain 
relapses. A secondary analysis of a prospective randomized 
trial of definitive radiochemotherapy (RT/CT) compared with 
neoadjuvant RT/CT+surgery was performed. 
Materials and Methods: Pts with pathologically proven 
operable IIIA(N2) / selected IIIB NSCLC received 3 cycles 
cisplatin/paclitaxel and neoadjuvant chemoradiotherapy to 
45 Gy (1.5 Gy bid/ concurrent cisplatin/ vinorelbine). Pts 
were reevaluated within an interdisciplinary panel during last 
week of RT/CT. Operable pts were randomized either to 
definitive RT/CT (arm A: risk- adapted boost to 65/71 Gy at 2 
Gy per fraction without break and concurrent 
cisplatin/vinorelbine) or surgery (arm B). Depending on 
institutional policy, PCI could be applied after completion of 
chemotherapy. 
Results: Between 1/2004 and 8/2012, 246 pts (70 F/176 M; 
stages, 75 T1-3 N2 / 80 T4 N0-1/ 91 T4 N2 or T1-3N3; 
histology, 95 SCC / 107 ADC / 44 other) were enrolled from 5 
centers, 161 patients were randomised (arm A: 80 pts, arm 
B:81 pts). Brain relapse as part of any relapse was observed 
in 33 randomised pts, isolated brain failures were detected in 
23 pts. Freedom from isolated brain relapse (FFIBR) at 2 
years was 84 (78-90)% for all patients, arm A 83 (73-93)%, 
arm B 81 (71-91)%. 42 pts recieved prophylactic cranial 
irradiation. PCI did not influence the incidence of isolated 
brain relapses (FFIBR at 2 years with or without PCI: 84 (70-
98)% vs 81 (73-89)%, p=0.93). Factors associated with a higher 
incidence of isolated brain relapses in univariate analysis 
were female gender (FFIBR at 2 years: 89 (81-97)% (male) vs 
72 (58-86)%, p=0.03) and TN-stage subgroup (FFIBR at 2 
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years: (T1-3 N2) 73 (59-87)% vs (T4 N0/1) 90 (82-98)% vs (T1-3 
N3/T4 N2) 83 (69-97), p=0.03). In multivariate proportional 
hazard regression analysis including the factors gender, PCI 
(yes/no), histology (scc/adeno), TN-subgroups, only gender 
remained significant (hazard ratio female vs male: 2.44 
[1;5.98], p=0.05). 5-Year survival from the diagnosis of 
isolated brain relapse onwards was 22% in contrast to 3% for 
patients after diagnosis of relapses at any site (p=0.08). 
Conclusions: A similar incidence of isolated brain relapses 
was found after trimodality or definitive RT/CT. The 
incidence of PCI was low in both arms without difference. 
Pts. with isolated brain relapse have a good prognosis after 
salvage therapy. Given this and the moderate incidence of 
brain metastases, PCI does not seem to provide a major 
therapeutic advantage.  
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Purpose/Objective: Biologically adaptive radiotherapy 
depends on early detection of response of tumor and/or 
normal tissue to allow timely adaptation of the remaining 
fractions. There is, however, little data on feasible time-
points to measure response of tumor and normal tissues with 
FDG PET. We are therefore currently performing a study with 
weekly FDG PET/CT in non-small cell lung cancer patients 
during therapy. The aim of this paper is to detect early 
response of normal tissues. 
Materials and Methods: All patients received 24 x 2.75 Gy 
concurrent with daily low dose cisplatinum. FDG PET/CT 
scans were made in treatment position directly before 
fractions 1, 6, 11, 16, and 21 and 1-3 months post-treatment. 
A region of interest (ROI) was defined as the part of the 
esophagus planned to receive more than 40 Gy physical dose, 
excluding the GTV and lymph nodes with a 5 mm margin. A 
lung ROI was defined as the region of lung tissue planned to 
receive more than 40 Gy excluding the primary GTV with a 5 
mm margin. Appropriate margins were used such that, after 
rigid registration based on the bony anatomy, the ROIs did 
not intersect tumor, heart or chest wall in any of the follow 
up scans. For the esophagus and lung ROIs, cumulative FDG 
uptake histograms were made for each weekly scan. For the 
long ROI, also the mean CT number was evaluated in each 
weekly scan. 
Results: In 7 out of 9 patients, a significantly increased SUV 
in the esophagus (SUV>4) could be seen before fractions 16 
and/or 21. The increased uptake occurred in regions of the 
esophagus planned to receive more than 63 Gy. However, the 
delivered dose at which esophagitis was first detected on PET 
ranged from 34 to 54 Gy over the 7 patients. Clinical 
complaints generally preceded PET findings. The patients 
without PET esophagitis had a planned esophagus dose of 
<50Gy. Interestingly, none of the patients showed increased 
FDG uptake in the lung ROI during treatment (SUV change 
from -0.18 to 0.17, all non-significant). Lung ROI CT number 
changes during treatment were small and often negative (-93 
to 29 HU, all non-significant). 
In the 5 available follow-up scans, only two taken 3 months 
after treatment showed changes in the lung ROI: the mean 
SUV increased 1.4-2, and the mean density 140-260 HU. In all 
follow-up scans the FDG uptake in the esophagus had 
subsided. 
Conclusions: This study shows that FDG uptake in the 
esophagus increases during chemoradiation at varying 
delivered doses and can be used to gauge early radiation 
damage. There was, however, no evidence of early PET or CT 
changes in the healthy lung receiving >40 Gy. The lack of CT 
response in this study (based on diagnostic CT) contradicts 
findings in the literature based on CBCT. The lack of early 
FDG uptake in the lung region receiving a high dose indicates 
that lung inflammation will not interfere with tumor response 
measurements.  
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Purpose/Objective: To investigate the correlation of lung 
dose volume parameters with radiation pneumonitis (RP) in 
non-small-cell lung cancer (NSCLC) and pulmonary 
metastases treated with stereotactic body radiotherapy 
(SBRT). 
Materials and Methods: From January 2006 to January 2014, 
72 patients with primary or metastatic lung tumors 
underwent SBRT with total dose of 40 Gy (47.22%) and 50 Gy 
(52.78%) in 5 fractions with Linac or Tomotherapy. The dose 
was prescribed to the isocenter, the fractionation schedule 
has been chosen according to diameter and location of the 
lesion (central vs peripheral). 54/72 (75%) patients had 
primary lung cancer and 18/72 (25%) patients had solitary 
secondary lung lesion. Dosimetric factors were extracted 
from the dose-volume histogram (DVH). PTV consisted of GTV 
plus 1 cm in cranial-caudal direction and 0.5 cm in others 
directions; after installation of Tomotherapy, expansion was 
0.5 cm in all directions. Median tumor diameter was 20 mm 
(range 10-60) and 11 mm (5-22), median GTV was 5.87 cc 
(0.88-27.90) and 3.34 cc (0.33-9.07), median PTV was 28.48 
cc (2.7-133.8) and 14.785 cc (7.3-113.3) for primary and 
secondary lung cancer, respectively. Response was evaluated 
with CT and/or FDG-PET imaging 3-4 months after the end of 
SBRT and every 4-6 months thereafter. Toxicity was 
evaluated according to CTCAE v3.0. We retrospectively 
analyzed clinical, treatment-related and dosimetric factors. 
Factors including total radiation dose, site of lesion, 
diameter, GTV, PTV, V5, V10, V20, V30 and mean lung dose 
(MLD) of ipsilateral lung were considered in order to evaluate 
the development of RP using the Cox proportional hazards 
model. The predictive accuracy for RP was assessed by using 
